Genetic engineering concept. Medical science. Scientific Laboratory.
image-

Beefing Up Cancer Treatments, With A Vaccine In Sight

Posted on

Cancer crusade: Stony Brook-based Applied DNA Sciences and Italian biopharma EvviVax are one step closer to a bona fide DNA-based cancer vaccine. FEBRUARY 17, 2022 By GREGORY ZELLER // New vaccines produced in part by a progressive Long Island biotech could significantly increase the efficacy of existing cancer treatments. The potential breakthrough – detailed this month in […]

Read More email

image-

Applied DNA, Evvivax Announce LinearDNA™ Vaccine Candidate Booster Yields 5-Fold Average Increase in Neutralizing Antibody Titers in Domestic Felines

Posted on

Applied DNA and Evvivax Announce that LinearDNA™ COVID-19 Vaccine Candidate Booster Yields 5-Fold Average Increase in Neutralizing Antibody Titers in Domestic Felines Manufactured by an enzyme and without bacteria, LinearDNA vaccine candidate is virus-free, plasmid-free DNA Vaccine candidate induced neutralizing titers in 100% of trial cohort Based on positive study results, companies plan to accelerate […]

Read More email

image-

Applied DNA Announces Linear DNA Orders from New Contract Research Customers for Use in RNA Vaccine and Adeno-Associated Virus Applications

Posted on

STONY BROOK, N.Y. – November 2, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that it received orders for its linear DNA to be evaluated in an RNA vaccine and Adeno-Associated Virus (AAV) production from two new contract research customers, […]

Read More email

image-

Applied DNA Secures Grant from National Grid Partnered with the New York State MEP to Support Manufacture of COVID-19 Diagnostic Kits and Vaccine Candidates

Posted on

STONY BROOK, N.Y. – June 9, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company,” “our”) announced today it secured a $40,000 economic development grant from National Grid to support the Company’s efforts associated with the manufacture of COVID-19-related therapeutics and diagnostics programs. National Grid is one of the largest investor-owned […]

Read More email

image-

Applied DNA Provides Update on Linear-DNA COVID-19 Vaccine Candidates Development Program

Posted on

STONY BROOK, N.Y. – June 8, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the  “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today provided an update related to the development of […]

Read More email

image-

Applied DNA and Takis Biotech Announce the Production of Neutralizing Antibodies Against SARS-CoV-2 After DNA Vaccination in Animals

Posted on

STONY BROOK, N.Y. and Rome, Italy – May 4, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company” or “we/our”) today announced with its COVID-19 vaccine development partner Takis Biotech (“Takis”) that the first injections of the DNA vaccine candidates against the Spike protein (product of the S gene) of the […]

Read More email

image-

Italian Biotech Startup Racing To Develop A Coronavirus Vaccine

Posted on

Four days before the first cases of COVID-19 were confirmed in Italy on January 31, a small biotech firm in the outskirts of Rome announced it was pivoting its business. Researchers at Takis Biotech, which had been focused on cancer treatments, would instead set about developing a vaccine for the rapidly spreading coronavirus. With the virus […]

Read More email

image-

LI Biotech Speeds COVID-19 Vaccine Candidates To Italy

Posted on

[vc_single_image image=”19473″ img_size=”large”] Cure bet: If vaccine candidates prepared by Applied DNA’s LinearDNA manufacturing system perform as well as plasmid-based candidates prepared by Italian biopharma Takis Biopharma, the cross-Atlantic collaboration may be on to something. APRIL 15, 2020 By GREGORY ZELLER // With preliminary lab tests looking good, an innovative Long Island biotech is rushing […]

Read More email

image-

Applied DNA Leverages COVID-19 Vaccine Development and Proprietary Linear DNA Manufacturing Capability to Design a High Sensitivity Diagnostic Kit for Virus Detection

Posted on

STONY BROOK, N.Y., March 19, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions, nucleic acid-based biotherapeutic development, and diagnostics, announced today the completion of design of a diagnostic kit for SARS-CoV-2 (the virus that causes the […]

Read More email

image-

Applied DNA COVID-19 Collaboration Partner Takis Biotech Receives Italy Ministry of Health Approval to Begin Testing of a Vaccine Candidate on Pre-Clinical Models

Posted on

STONY BROOK, N.Y., March 18, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”) today announced that its COVID-19 collaboration partner, Takis Biotech, a Rome, Italy-based a company focused on the development of cancer vaccines founded by scientists from Merck Research Laboratories, has received approval from the Italy’s Ministry of Health to begin a […]

Read More email

image-

Stony Brook firm working on coronavirus vaccine

Posted on

A Stony Brook anti-counterfeiting company is seeking to adapt its DNA expertise to create a coronavirus vaccine with an Italian biotechnology partner. Applied DNA Sciences Inc. on Monday announced that it is expanding its alliance with Rome-based Takis Biotech on four potential vaccines to test on animals. In February, the companies announced a joint development […]

Read More email

image-

Pharmaceutical Technology | Applied DNA, Takis Biotech design four Covid-19 vaccine candidates

Posted on

[vc_single_image image=”19103″ img_size=”large” el_class=”graphic”] The PCR-produced linear DNA is expected to accelerate vaccine production. Applied DNA Sciences and Takis Biotech have designed four Covid-19 vaccine candidates to help protect against the novel coronavirus. The companies plan to manufacture the DNA vaccine candidates using PCR-based DNA (LinearDNA) manufacturing systems for preclinical testing in animals. Last month, Applied […]

Read More email

image-

Applied DNA Speeds Coronavirus Vaccines Toward Tests

Posted on

MARCH 2, 2020 By GREGORY ZELLER // Just weeks after announcing an expanded international collaboration targeting the menacing novel coronavirus, Applied DNA Sciences is preparing to mass-produce four potential vaccines. Leveraging the Stony Brook-based biotech’s unique DNA-manufacturing abilities, Rome, Italy-based Takis Biotech will test potential vaccines against the coronavirus (now going by COVID-19) in laboratory mice, on a large scale. Applied […]

Read More email

image-

Applied DNA Sciences (NASDAQ: APDN) Updates on COVID-19 Collaboration with Takis Biotech, 4 Preclinical LinearDNA™ Vaccine Candidates Designed

Posted on

STONY BROOK, N.Y., and ROME, ITALY – March 2, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions, nucleic acid-based biotherapeutic development, and liquid biopsies for cancer diagnostics, and Takis Biotech (“Takis”), a company focused on the development of […]

Read More email

image-

Applied DNA To Speed Up Coronavirus Countermeasures

Posted on

By GREGORY ZELLERLook out, coronavirus – Applied DNA is coming for you. Adding to its growing portfolio of cutting-edge Polymerase Chain Reaction-based projects, Stony Brook-based Applied DNA Sciences is expanding its Joint Development Agreement with Italian R&D company Takis Biotech, with the headline-making 2019-nCoV in their sights. Already hot on the trail of new cancer vaccines, the partners will […]

Read More email

image-

Applied DNA, Takis Biotech partner on coronavirus vaccine

Posted on

[vc_single_image image=”19103″ img_size=”large” el_class=”graphic”] The PCR-produced linear DNA is expected to accelerate vaccine production. Applied DNA Sciences has extended its partnership with Takis Biotech to include the development of a vaccine for 2019-nCoV coronavirus. LineaRx, a subsidiary of Applied DNA, will work with Takis Biotech on preclinical development of a linear DNA vaccine based on […]

Read More email

image-

Applied DNA Sciences Subsidiary, LineaRx, and Takis Biotech Collaborate for Development of a Linear DNA Vaccine Candidate Against Wuhan Coronavirus 2019-nCoV

Posted on

Expanded Joint Development Agreement Serves as Basis for Preclinical Linear DNA Vaccine; Linear DNA Platform Will be the Production Framework STONY BROOK N.Y., February 7, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions, nucleic acid-based biotherapeutic […]

Read More email

image-

Applied DNA Sciences Reports 14 Development Customers for its Linear DNA Manufacturing Platform

Posted on

STONY BROOK, N.Y., November 25, 2019 –  Applied DNA Sciences, Inc. (NASDAQ: APDN, Applied DNA, “the Company”) announced today that LineaRx, Inc., its majority-owned subsidiary focused on next-generation biotherapeutics and diagnostics, has grown its customer base to fourteen companies currently testing its linear DNA manufacturing platform for the development of nucleic acid-based therapies and diagnostics.  The Company […]

Read More email

image-

‘Linear DNA’ Combo Shows Punch In Cancer Fight

Posted on

[vc_single_image image=”17928″ img_size=”large”] By GREGORY ZELLER //SEPTEMBER 19, 2019 Mark another impressive victory for LineaRX, this time in a two-front battle against cancer. The Stony Brook-based biotech with innovation in its DNA (literally) has lent its unique DNA-sequencing technology to two vaccine-candidate tests run by Italian R&D company Takis Biotech, which is hot on the trail of […]

Read More email

image-

Applied DNA Subsidiary LineaRx and Takis/Evvivax Progress Linear DNA for Use as Cancer Vaccine Candidates

Posted on

STONY BROOK, N.Y., March 1, 2019 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx”), its wholly-owned subsidiary focused on next-generation biotherapeutics, will ship TK7 and ConTRT amplicons to Takis/Evvivax next week as part of the companies’ Joint Development Agreement (“JDA”) entered […]

Read More email

image-

LineaRx to Collaborate with Italian Companies Takis and Evvivax on Cancer Vaccines

Posted on

Published: Sep 20, 2018 By Mark TerryLineaRx, a subsidiary of Applied DNA Sciences, has entered into a Joint Development Agreement with Takis SRL and Evvivax SLR. They will focus on developing anti-cancer vaccines. Under the terms of the deal, LineaRx and Takis and Evvivax will work together to develop linear DNA expression vectors of two of Takis/Evvivax’s anti-cancer vaccine candidates. They will use […]

Read More email

image-

Applied DNA Subsidiary, LineaRx, Inc. Signs Joint Development Agreement with Takis and Evvivax to Develop Linear-DNA Based Anti-Cancer Vaccines

Posted on

STONY BROOK N.Y., September 20, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) announced today that LineaRx, Inc. (“LineaRx”), its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement (the “Agreement”) with Takis S.R.L. and Evvivax S.R.L. (“Takis/Evvivax”), biotechnology companies focused on the discovery and development of […]

Read More email